================================================================================


                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON D.C. 20549

                                   FORM 10-QSB
(Mark One)

[X]   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
      EXCHANGE ACT OF 1934

      For the quarterly period ended April 30, 2004

[_]   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
      EXCHANGE ACT OF 1934

      For the transition period from _________________ to _________________


                         Commission File No.: 000-26753


                              AMAZON BIOTECH, INC.
             (Exact name of registrant as specified in its charter)

              UTAH                                             87-0416131
 (State or other jurisdiction of                            (I.R.S. Employer
 incorporation or organization)                            Identification No.)

                         43 WEST 33RD STREET, SUITE 405
                               NEW YORK, NY 10001
                    (Address of principal executive offices)

                   Issuer's telephone number: (212) 695-3003

                               ASYST CORPORATION
                           6170 SOUTH 380 WEST, #250
                               MURRAY, UTAH 84107
              (Former name, former address and former fiscal year,
                         if changed since last report)

                                ___________________

Check whether the registrant filed all documents and reports required to be
filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.  Yes [X] No [_]

                      APPLICABLE ONLY TO CORPORATE ISSUERS

As of June 15, 2004, 23,390,632 shares of our common stock were outstanding.

Transitional Small Business Disclosure Format:  Yes [_]  No [X]

================================================================================

<PAGE>



PART 1: FINANCIAL INFORMATION

ITEM 1 - CONDENSED FINANCIAL STATEMENTS

                              AMAZON BIOTECH, INC.
                        (A Development Stage Enterprise)
                          (Formerly ASYST Corporation)

                                 BALANCE SHEET


                                                                       April 30,
                                                                         2004
                                                                      ---------

                                     ASSETS

CURRENT ASSETS
  Cash                                                                $  31,997
                                                                      ---------

                     Total Current Assets                                31,997

OFFICE EQUIPMENT, net                                                     1,006

INTANGIBLE ASSETS - Production rights                                       300
                                                                      ---------

                                                                      $  33,303
                                                                      =========

                      LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES
  Accrued expenses                                                    $   3,486
                                                                      ---------

                     Total Current Liabilities                            3,486

STOCKHOLDER'S EQUITY
  Preferred stock, authorized 2,000,000 shares;
    $0.001 per value; no shares issued and outstanding
  Common stock, authorized 50,000,000
    Shares; $0.001 par value; issued
    and outstanding 21,367,632 shares at April 30, 2004               $  21,368
  Additional contributed capital                                        213,832
  Deficit accumulated during the development stage                     (205,383)
                                                                      ---------

      Stockholder Equity Deficit                                         29,817
                                                                      ---------
                                                                      $  33,303
                                                                      =========


                See accompanying notes to financial statements.

                                       2
<PAGE>

                              AMAZON BIOTECH, INC.
                        (A Development Stage Enterprise)
                          (Formerly ASYST Corporation)

                             STATEMENT OF NET LOSS


<TABLE>
<CAPTION>
                                                                                   Cumulative
                                                            Three Months           Inception
                                                                Ended          October 1, 2002 to
                                                            April 30, 2004       April 30, 2004
                                                         -------------------   -------------------
ADMINISTRATIVE EXPENSES

<S>                                                      <C>                   <C>
   Consulting fees                                       $           117,453   $           117,453
   Stock based compensation                                           42,900                42,900
   Other general office expenses                                      44,985                44,985
   Depreciation                                                           45                    45
                                                         -------------------   -------------------

               Total Administrative Expenses                         205,383               205,383
                                                         -------------------   -------------------

NET LOSS FOR THE PERIOD                                  $          (205,383)  $          (205,383)
                                                         ===================   ===================
NET LOSS PER  SHARE OF COMMON STOCK (basic and diluted)  $             (0.05)  $             (.005)
                                                         ===================   ===================
WEIGHTED AVERAGE NUMBER OF COMMON
   SHARES OUTSTANDING                                              3,904,508             3,904,508
                                                         ===================   ===================
</TABLE>


                  See accompanying notes to financial statements.

                                       3
<PAGE>

                              AMAZON BIOTECH, INC.

                        (A Development Stage Enterprise)
                          (Formerly ASYST Corporation)
                            STATEMENT OF CASH FLOWS
<TABLE>
<CAPTION>
                                                                               Cumulative
                                                         For the Three          Inception
                                                          Months Ended      October 10, 2002 to
                                                         April 30, 2004        April 30, 2004
                                                      -------------------   -------------------

CASH FLOWS FROM OPERATING ACTIVITIES
<S>                                                   <C>                   <C>
   Net loss                                           $          (205,383)  $          (205,383)
   Stock based compensation                                        42,900                42,900
   Depreciation expense                                                45                    45
     Changes in assets and liabilities
     Increase in accrued expenses                                   3,486                 3,486
                                                      -------------------   -------------------

     Net cash used in operating activities                       (158,952)             (158,952)

CASH FLOWS FROM INVESTING ACTIVITIES

   Purchase of office equipment                                    (1,051)               (1,051)
                                                      -------------------   -------------------

     Net cash used in investing activities                         (1,051)               (1,051)

CASH FLOWS FROM FINANCING ACTIVITIES

  Sale of common stock                                            192,000               192,000
                                                      -------------------   -------------------

     Net cash provided by financing activities                    192,000               192,000
                                                      -------------------   -------------------

     Net increase in cash                                          31,997                31,997
                                                      -------------------   -------------------

CASH AT BEGINNING OF PERIOD
                                                      -------------------   -------------------

CASH AT END OF PERIOD                                 $            31,997   $            31,997
                                                      ===================   ===================
</TABLE>


                See accompanying notes to financial statements.

                                       4
<PAGE>

                              AMAZON BIOTECH, INC.

                        (A Development Stage Enterprise)
                          (Formerly ASYST Corporation)

                         NOTES TO FINANCIAL STATEMENTS
                                  (Unaudited)


NOTE A - CONDENSED FINANCIAL STATEMENTS

In the opinion of the Company, the accompanying unaudited condensed financial
statements include all adjustments (consisting only of normal recurring
accruals) which are necessary for a fair presentation of the results for the
periods presented. Certain information and footnote disclosure, normally
included in the financial statements prepared in accordance with generally
accepted accounting principles, have been condensed and omitted. The results of
operations for the three months ended April 30, 2004 are not indicative of the
results of operations for the year ended July 31, 2004. The condensed financial
statements should be read in conjunction with the Company's financial statements
included in its annual Form 10 KSB for the year ended July 31, 2004 and its Form
8K/A filed February 20, 2004.

NOTE B - REVERSE MERGER

On February 20, 2004, Amazon Biotech, Inc., a private company, acquired
16,000,000 shares of ASYST Corporation common stock in an exchange of shares,
thereby obtaining control of the Company. Subsequent to the acquisition, Amazon
Biotech, Inc. controlled 99% of the outstanding common stock of the Company. In
this connection, the Company became a wholly owned subsidiary of Amazon Biotech,
Inc. and its officers and directors replaced the Company's officers and
directors. Prior to the merger, ASYST Corporation was a non-operating public
shell corporation. Pursuant to Securities and Exchange Commission rules, the
merger of a private operating company into a non-operating public shell
corporation with nominal net assets is considered a capital transaction.
Accordingly, for accounting purposes, the merger has been treated as an
acquisition of Amazon Biotech, Inc. by the Company and a recapitalization of the
Company. Since the merger is a recapitalization of the Company and not a
business combination, pro-forma information is not presented.

NOTE C - STOCKHOLDERS' EQUITY

On February 23, 2004, the Company issued 750,000 shares of its common stock to
an investor for $2,000. Additionally, on March 16, 2004, the Company sold
200,000 shares of its common stock at $0.50 per share to the same investor.

On March 3, 2004, the company issued 4,290,000 shares to consultants for
services rendered. The shares were valued @ $0.01 per share.

In March and April 2004, the company sold 90,000 shares at $1.00 per share to
investors. The shares have not yet been issued but have been included in the
financial statements as issued.

NOTE D - CONSULTING FEES

Consulting fees consist of legal and accounting ($12,467) and fees for product
development ($104,986). Product development fees are paid principally to
individuals who are deemed to be related parties to the Company.

                                       5
<PAGE>

ITEM 2 - PLAN OF OPERATION.

      The following discussion and analysis should be read in conjunction with
our unaudited condensed financial statements and related notes included in this
report. This report contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. The statements contained
in this report that are not historic in nature, particularly those that utilize
terminology such as "may," "will," "should," "expects," "anticipates,"
"estimates," "believes," or "plans" or comparable terminology are
forward-looking statements based on current expectations and assumptions.

      Various risks and uncertainties could cause actual results to differ
materially from those expressed in forward-looking statements. All
forward-looking statements in this document are based on information currently
available to us as of the date of this report, and we assume no obligation to
update any forward-looking statements. Forward-looking statements involve known
and unknown risks, uncertainties and other factors that may cause the actual
results to differ materially from any future results, performance or
achievements expressed or implied by such forward-looking statements.

GENERAL

OUR CORPORATE HISTORY

      On February 20, 2004, Asyst Corporation acquired 100% of the outstanding
common stock of Amazon Biotech, Inc., a Delaware corporation pursuant to a
securities purchase agreement and plan of reorganization. Under the plan of
reorganization, Asyst issued 16,000,000 shares of its common stock to the
stockholders of Amazon Biotech in exchange for all of the outstanding shares of
common stock of Amazon Biotech. Pursuant to the plan of reorganization, 131,250
shares of Asyst common stock were cancelled. Upon the completion of the
reorganization, Angelo Chinnici, M.D. and Philip Drachman, the former directors
of Amazon Biotech, were appointed as directors of Asyst.

      On March 10, 2004, Asyst amended its articles of incorporation to change
its name to "Amazon Biotech, Inc."

PLAN OF OPERATION

      Amazon Biotech is a newly established pharmaceutical company which owns
the rights to Abavca/AMZ 0026, a potential immunomodulator drug developed for
use in the treatment of the HIV virus. Amazon Biotech recently acquired the
rights to the Abavca/AMZ 0026 product line from Advanced Plant Pharmaceuticals,
Inc.

      AMZ 0026 was developed by a group of scientists after more than 12 years
of intense research. Many users of AMZ 0026 caplets have reported increased CD4
and HGB counts as well as general improvements in energy levels, weight gain,
and overall well being. These results were borne out in an 18-month clinical
study, which included 30 test subjects who had depressed immune systems.

      Abavca/AMZ 0026 has been given an IND status and has been approved for
Phase I/II clinical studies by the FDA. Amazon Biotech intends to initiate Phase
II clinical studies of Abavca/AMZ 0026 within the next 12 months, with an
eventual goal of a joint venture with another pharmaceutical company to conduct
Phase III trials.

      Amazon Biotech also owns the rights to a natural hair growth product that
contains proprietary herbal ingredients. Amazon Biotech intends to conduct a
small double blind study on this product within the next twelve months.

      Amazon Biotech currently has limited working capital with which to satisfy
its cash requirements, and it will require significant additional capital in
order to fund the Phase I/II clinical studies of Abavca/AMZ. Amazon anticipates
that we will need approximately $4,000,000 in additional working capital in
order to sustain operations for the next 12 months. Amazon Biotech has recently
completed two private placements of common stock, receiving gross proceeds of
approximately $102,000. In addition, Amazon Biotech is conducting a private
placement of units consisting of common stock and warrants. As of the date
hereof, Amazon Biotech has received gross proceeds of $120,000 in this private
placement. Amazon is continuing to seek to fund its capital requirements over
the next 12 months from the additional sale of its securities. It is possible
that Amazon Biotech will be unable to obtain sufficient additional capital
through the sale of its securities as needed.

                                       6
<PAGE>

      In the event that Amazon is able to raise sufficient operating capital, it
intends to hire increase from four to six employees. It may also purchase
laboratory equipment with a portion of any capital proceeds.

      We intend to retain any future earnings to retire debt, finance the
expansion of our business and any necessary capital expenditures, and for
general corporate purposes.

ITEM 3 - CONTROLS AND PROCEDURES

      Our disclosure controls and procedures are designed to ensure that
information required to be disclosed in reports that we file or submit under the
Securities Exchange Act of 1934 is recorded, processed, summarized and reported
within the time periods specified in the rules and forms of the Securities and
Exchange Commission. Our Chief Executive Officer and the Chief Financial Officer
have reviewed the effectiveness of our "disclosure controls and procedures" (as
defined in the Securities Exchange Act of 1934 Rules 13a-14(c) and 15d-14(c))
within the last ninety days and have concluded that the disclosure controls and
procedures are effective to ensure that material information relating to
Excalibur and its consolidated subsidiaries is recorded, processed, summarized,
and reported in a timely manner. There were no significant changes in our
internal controls or in other factors that could significantly affect these
controls subsequent to the last day they were evaluated by our Chief Executive
Officer and Chief Financial Officer.

PART II: OTHER INFORMATION

ITEM 1 - LEGAL PROCEEDINGS

      None.

ITEM 2 - CHANGES IN SECURITIES

      (a) Effective February 12, 2004, the Company effected a one for eight
reverse split of its outstanding common stock that decreased the outstanding
securities to 168,882; as a result, the OTC Bulletin Board symbol of the Company
was changed to "ASYC."

      (b) None.

      (c) On February 20, 2004, the Company acquired 100% of the outstanding
common stock of Amazon Biotech, Inc., a Delaware corporation pursuant to a
securities purchase agreement and plan of reorganization. Under the plan of
reorganization, the Company issued 16,000,000 shares of its common stock to the
stockholders of Amazon Biotech in exchange for all of the outstanding shares of
common stock of Amazon Biotech. Pursuant to the plan of reorganization, 131,250
shares of the Company's common stock were cancelled. Upon the completion of the
reorganization, Angelo Chinnici, M.D. and Philip Drachman, the former directors
of Amazon Biotech, were appointed as directors of the Company. Effective March
10, 2004, the Company changed its name to Amazon Biotech, Inc.; as a result the
OTC Bulletin Board symbol of the Company was changed to "AMZB.OB.".

      On February 23, 2004, the Company issued 750,000 shares of its common
stock in a private placement for $2,000. The issuance was exempt under Section
4(2) of the Act.

      On March 16, 2004, the Company sold 200,000 shares of its common stock in
a private placement at $0.50 per share. The issuance was exempt under Section
4(2) of the Act.

      From March 25, 2004 through the end of the quarter, the Company issued an
aggregate of 90,000 shares of its common stock in a private placement at $1.00
per share. In addition, the Company issued warrants to purchase an aggregate of
180,000 shares at a strike price of $6.00 per share. The issuance was exempt
under Section 4(2) of the Act.

      (d)   None.

                                       7
<PAGE>

ITEM 3 - DEFAULT UPON SENIOR SECURITIES

      None.

ITEM 4 - SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

      None.

ITEM 5 - OTHER INFORMATION

      None.

ITEM 6 - EXHIBITS AND REPORTS ON FORM 8-K

      (a) Exhibits.

Item
No.     Description                            Method of Filing
---     -----------                            ----------------

31.1    Certification of Angelo Chinnici,      Filed electronically herewith.
        M.D. pursuant to Rule 13a-14(a)
31.2    Certification of Philip Drachman       Filed electronically herewith.
        pursuant to Rule 13a-14(a)
32.1    Chief Executive Officer                Filed electronically herewith.
        Certification pursuant to 18 U.S.C.
        ss. 1350 adopted pursuant to Section
        906 of the Sarbanes Oxley Act of
        2002
32.2    Chief Financial Officer                Filed electronically herewith.
        Certification pursuant to 18 U.S.C.
        ss. 1350 adopted pursuant to Section
        906 of the Sarbanes Oxley Act of
        2002



      (b)   Reports on Form 8-K

      Current report on Form 8-K filed March 8, 2004 reporting the acquisition
of 100% of the capital stock of Amazon Biotech, Inc., and the reorganization of
the registrant, as amended by current report on Form 8-K filed May 11, 2004.

                                       8
<PAGE>

                                   SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.


                                      Amazon Biotech, Inc.


June 17, 2004                         /s/ Angelo Chinnici, M.D.
                                      ------------------------------------------
                                      Angelo Chinnici, M.D.
                                      Chief Executive Officer
                                      (Principal Executive Officer)

June 17, 2004                         /s/Philip Drachman
                                      ------------------------------------------
                                      Philip Drachman
                                      President
                                      (Principal Financial Officer and Principal
                                      Accounting Officer)

                                       9